MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1

Historical Holders from Q1 2014 to Q3 2020

Type / Class
Debt / NOTE 4.500% 7/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 across Reporting Periods

Period Principal Value Change Price (% of par) Investors
2020 Q3 $0 $0 -$24,000 0
2020 Q2 $26,000 $24,000 -$23,000 96% 2
2020 Q1 $51,000 $47,000 92% 3
2019 Q4 $51,000 $47,000 $0 92% 3
2019 Q3 $26,000 $24,000 $0 96% 2
2019 Q2 $26,000 $24,000 96% 2
2019 Q1 $26,000 $24,000 96% 2
2018 Q4 $26,000 $24,000 +$23,000 96% 2
2018 Q3 $1,000 $1,000 100% 1
2018 Q2 $1,000 $1,000 100% 1
2018 Q1 $1,000 $1,000 100% 1
2017 Q4 $1,000 $80,000 -$42,502,000 8,000% 1
2017 Q3 $48,620,000 $42,503,000 -$3,266,849 85.71% 10
2017 Q2 $52,419,000 $38,302,000 74.48% 9
2017 Q1 $52,419,000 $43,558,000 -$179,247 83.8% 9
2016 Q4 $52,609,000 $49,876,000 -$2,913,950 94.1% 8
2016 Q3 $52,604,000 $65,197,000 +$105,815 124.85% 11
2016 Q2 $53,214,000 $59,218,000 -$87,974,811 111.63% 12
2016 Q1 $115,416,000 $173,610,000 +$24,942,508 149.51% 15
2015 Q4 $98,913,000 $145,895,000 -$25,839,174 147.88% 15
2015 Q3 $114,919,000 $180,255,000 +$431,151 157.26% 16
2015 Q2 $113,394,000 $238,347,000 -$7,108,800 209.67% 16
2015 Q1 $116,925,000 $234,281,000 +$2,097,484 200.47% 15
2014 Q4 $116,770,000 $221,898,000 +$5,525,734 190.15% 16
2014 Q3 $113,943,000 $177,353,000 +$10,432,922 155.44% 16
2014 Q2 $109,690,000 $147,492,000 +$4,620,806 134.35% 20
2014 Q1 $108,007,000 $109,741,000 +$319,874 101.47% 24